title: Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study.
abstract: OBJECTIVE
  To compare a fixed combination of 0.03% bimatoprost and 0.5% timolol (BTFC) with latanoprost monotherapy (LM) in treatment-naïve patients with open-angle glaucoma (OAG) and risk factors for glaucomatous progression.
  
  
  METHODS
  Patients were enrolled at 15 sites in Spain and Portugal, and were randomized 1:1 to BTFC or LM. Patients instilled one drop of medication once per day at 8 pm for 12 weeks. The primary outcome was change in intraocular pressure (IOP) at 12 weeks.
  
  
  RESULTS
  Of 81 patients enrolled, 43 were randomized to BTFC and 38 to LM. Mean (SD) change in IOP from baseline to 12 weeks was significantly greater for BTFC than for LM: -13.5 mmHg (4.48) versus -11.4 mmHg (3.19), respectively (P=0.003). Similarly, at 12 weeks, significantly more BTFC patients than LM patients had IOP reductions of ≥40% (74.4% versus 47.4%, P=0.015) or ≥50% (46.5% versus 15.8%, P=0.003). Adverse events were more frequent with BTFC than with LM (33 versus 13 events), but most were mild in severity. The only serious adverse event (colon cancer) was adjudged unrelated to the study medication.
  
  
  CONCLUSIONS
  BTFC was effective and well tolerated in treatment-naïve patients with OAG at high risk of progression.
authors.affiliation: Department of Ophthalmology, Hospital Doce de Octubre, Universidad Complutense, Madrid, Spain.
authors.forename: Esperanza
authors.initials: E
authors.lastname: Gutierrez-Diaz
authors.affiliation: Department of Ophthalmology, Hospital de São João, Porto, Portugal.
authors.forename: Jose
authors.initials: J
authors.lastname: Silva Cotta
authors.affiliation: Department of Ophthalmology, Hospital Ramón y Cajal, IRYCIS, Universidad Alcalá, Madrid, Spain.
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Muñoz-Negrete
authors.affiliation: Department of Ophthalmology, Hospital Universitario Príncipe de Asturias, Madrid, Spain.
authors.forename: Consuelo
authors.initials: C
authors.lastname: Gutierrez-Ortiz
authors.affiliation: Medical Affairs, Allergan Holdings Ltd, Marlow, UK.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Morgan-Warren
authors.affiliation: Medical Affairs, Allergan Holdings Ltd, Marlow, UK.
authors.forename: John
authors.initials: J
authors.lastname: Maltman
keywords: fixed combinations; open-angle
references.citation: J Ocul Pharmacol Ther. 2010 Oct;26(5):503-11
references.pmid: 20874498
references.citation: Eur J Ophthalmol. 2012 Jan-Feb;22(1):5-18
references.pmid: 22167538
references.citation: Arch Ophthalmol. 2006 Nov;124(11):1553-7
references.pmid: 17102001
references.citation: J Glaucoma. 2005 Aug;14(4):267-70
references.pmid: 15990605
references.citation: J Glaucoma. 2008 Dec;17(8):667-73
references.pmid: 19092464
references.citation: Clin Ophthalmol. 2009;3:337-9
references.pmid: 19668587
references.citation: Br J Ophthalmol. 2010 Feb;94(2):209-13
references.pmid: 19825835
references.citation: Eur J Ophthalmol. 2007 Jan-Feb;17(1):53-62
references.pmid: 17294383
references.citation: Curr Med Res Opin. 2010 Sep;26(9):2213-9
references.pmid: 20673200
references.citation: Ophthalmology. 2007 Nov;114(11):1965-72
references.pmid: 17628686
references.citation: Br J Ophthalmol. 2013 Jul;97(7):857-61
references.pmid: 23686322
references.citation: J Clin Epidemiol. 2009 Dec;62(12):1279-83
references.pmid: 19716679
references.citation: Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4226-31
references.pmid: 18502991
references.citation: Eye (Lond). 2003 Jan;17(1):41-6
references.pmid: 12579169
references.citation: J Glaucoma. 2008 Apr-May;17(3):211-6
references.pmid: 18414107